权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD

发现 EB 病毒相关淋巴瘤和 PTLD 的新治疗方案

基本信息

批准号：
8245223
负责人：
Richard M Longnecker
金额：
$ 7.96万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-07-14 至 2013-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8245223
关键词：
Adult Apoptosis Apoptotic B-Cell Activation B-Cell Development B-Lymphocytes Benign Burkitt Lymphoma Cell Survival Cells Clinical Treatment Data Development Disease Drug Delivery Systems EBV-associated disease EBV-associated malignancy Epstein-Barr Virus Infections Epstein-Barr Virus latency Epstein-Barr Virus-Related Lymphoma Epstein-Barr pathogenesis Foundations Gene Expression Goals Growth HIV Infections Health Hematologic Neoplasms Herpesviridae Hodgkin Disease Human Human Herpesvirus 4 Immunosuppression In Vitro Individual Laboratories Lead Leukocytes Life Lymphocyte Lymphoma Lymphomagenesis Lymphoproliferative Disorders Malignant Neoplasms Mediating Membrane Proteins Memory B-Lymphocyte Methodology Methylcellulose Modeling Monitor Mus Nasopharynx Carcinoma Non-Hodgkin&apos s Lymphoma Organ Transplantation Pathogenesis Pathway interactions Pharmaceutical Preparations Population Preclinical Drug Evaluation Prevention Protein Tyrosine Kinase Proteins Receptors, Antigen, B-Cell Research Risk Satellite Viruses Signal Pathway Signal Transduction Signal Transduction Pathway Spleen Staging Testing Therapeutic Transgenic Mice Transgenic Model Viral Proteins Virus cellular targeting human FRAP1 protein in vivo infected B cell inhibitor/antagonist insight latent infection notch protein novel prevent promoter receptor expression receptor function research study transcription factor tumor

项目摘要

Our specific goals are to identify drugs that will target Epstein-Barr virus (EBV) latent infections and EBV- associated hematologic cancers and proliferative disorders that occur in the human host. EBV is a herpesvirus that infects approximately 95% of the human population and usually results in the benign, latent infection of memory B lymphocytes for the life of the host. EBV is unique, however, in that latent infection can lead to virus- associated malignancies such as Burkitts lymphoma (BL), Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), and nasopharyngeal carcinoma (NPC). Understanding EBV latent infection provides insight into the pathogenesis of EBV-associated disease and may lead to targeted therapies to prevent or treat EBV- associated malignancies. Latent membrane protein 2A (LMP2A) is an EBV protein expressed in latently infected B-lymphocytes and detected in EBV-associated malignancies. LMP2A alters and mimics normal B cell signaling pathways induced by the B cell receptor (BCR) to prevent apoptosis and prolong cell survival. LMP2A function is dependent on numerous cellular proteins including the Lyn and Syk protein tyrosine kinases (PTKs), and the Ras/PI3K/Akt pathway. We hypothesize that LMP2A is essential for EBV latency and EBV-associated pathogenesis by altering normal BCR function and activating intracellular pro-survival and anti-apoptotic pathways that block important cellular checkpoints such as Myc-induced apoptosis. Using a novel in vivo murine model of EBV latency developed in our laboratory and a novel in vitro methodology, we will test pharmacological inhibitors of LMP2A-activated proteins. As described in the proposal, many of these inhibitors are currently being tested and are in early stages of human trials for treatment of other diseases unrelated to EBV-associated disease. Promising data using our murine transgenic model would provide important data to justify proposed human studies with EBV-related lymphomas. Finally, other targets may be identified in our proposed research that effectively target LMP2A function. Overall, the studies proposed will test the feasibility of LMP2A signaling inhibition, will determine the most effective agents to inhibit LMP2A signaling activity, will provide a foundation for in vivo drug developmental studies aimed at the eradication of EBV latency as treatment or prevention for EBV-associated malignancies, and may offer therapeutic options for EBV- associated cancers such as EBV-associated Hodgkin lymphoma and NHL. Epstein-Barr virus (EBV) is a herpesvirus that ubiquitously infects the human population resulting usually in the benign, latent infection of white blood cells. However, EBV infection and the resulting latent infection can lead to virus-associated proliferative disorders such as Burkitts lymphoma and Hodgkin lymphoma. Our specific goals are to identify drugs that target EBV latent infections and EBV-associated lymphomas that occur in the human host by using inhibitors of cell proteins targeted by EBV.

我们的具体目标是确定针对eb病毒（EBV）潜伏感染和EBV-的药物